Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-23-046462

Chief R&D Officer sold 9,703 shares at $0.78 ($7,568)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2023-08-16 Sale −9,703 $0.78 $7,568 283,685 D: show line 1 in the form
Open-market sales · 9,703 sh · avg $0.78 · $7,568
Loading xslF345X05/doc4.xml…